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duration of onset of bacteremia after UCBT with a median of 15
days and the duration of 3-34 days, compared with after UBMT.
Graft-vs-host disease of grade II, III or IV occurred in 2 of 10
patients who survived more than 100 days after UCBT and in 15
of 40 after UBMT. The TRM and EFS at 2 years post-transplant
in patients at an early disease stage were 12.5 % and 75.0 % after
UCBT and 6.5% and 68.7% after UBMT. Conclusion: UCB
transplantation in adults is associated with delayed neutrophil re-
covery and longer duration of bacteremia at early time points after
transplantation. The TRM (12.5%) and EFS (75.0%) at 2 years
after transplantation were similar to our experience of UBMT.
Thus, parallel to the search for a matched unrelated donor, search-
ing for an adequate UCB unit should be initiated.
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REDUCED-INTENSITY CONDITIONING IS VERY EFFECTIVE IN PATIENTS
WITH INDOLENT LYMPHOPROLIFERATIVE DISORDERS AND HAS LIM-
ITED SUCCESS IN ACUTE LYMPHOBLASTIC LEUKEMIA. EXPERIENCE IN
A SINGLE INSTITUTION IN ME´XICO
Gomez-Almagur, D., Gutierrez-Aguirre, C.H., Cantu-Rodriguez, O.G.,
Gonzalez-LLano, O., Jaime-Perez, J.C., Mancillas-Guerra, C.,
Herrera-Garza, J.L. Hospital Universitario, U.A.N.L., Monterrey,
Nuevo Leon, Mexico.
The published experience of reduced-intensity allogeneic stem
cell transplantation (ASCT) for acute lymphoblastic leukemia
(ALL) remains limited. Some studies have been shown that the
graft-versus-leukemia effect is not powerful enough to make this
conditioning regimen useful in ALL. On the other hand, indolent
lymphoproliferative disorders (ILD) has been associated, in some
studies, with high mortality when reduced-intensity ASCT was
used as a piece of a treatment. We evaluated the outcome and
survival of both ALL and ILD patients who received a reduced-
intensity SCT in our hospital. A total of 20 high risk patients in
ALL group and 10 patients in ILD group (3 with chronic lympho-
cytic leukemia and 7 with indolent non Hodgkin lymphoma) were
included. The median age for both groups was 19 years and 43
years respectively. All patients received cyclophosphamide IV 300
mg/m2and ﬂudarabine 30 mg/m2 for 3 days (6, 5, 4) and
cyclophosphamide IV 50 mg/kg/day or busulphan 4 mg/kg/day for
2 days (3, 2) as conditioning regimen. In 20 patients (67%) it
was administrated as ambulatory setting. Daily oral cyclosporine
and methotrexate (days 1, 3, 5) were delivery as prophylactic
GVHD. The median CD34 cell dose infused was 5.37  106 in
ALL and 5.2  106 in ILD group. Neutrophil recovery to 0.5 
109/l was observed at day 13 (median) in both groups. Acute and
chronic GVHD was developed more frequently in ILD group than
in ALL group (40% vs. 25%). Relapse was higher in ALL group
(65%) than in ILD group (10%) and this complication was the
principal cause of death in both groups (50% vs. 10%). In all, 19
patients died, 16 (80%) patients in ALL group and 3 (30%) pa-
tients in ILD group. We conclude that reduced-intensity ASCT in
high-risk ALL patients could not be the best choice for treatment.
We believe that this conditioning regimen can be used successfully
in treatment of patients with ILD, however, in ALL more studies
and new ideas are needed.
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REDUCED INTENSITY CONDITIONING (RIC) FOR ALLOGENEIC HEMA-
TOPOIETIC STEM CELL TRANSPLANTATION (HCT) IN PATIENTS WITH
AML EVOLVED FROM MDS OR THERAPY RELATED AML
O’Donnell, M.R., Roberto, R., Stein, A.S., Palmer, J., Slovak, M.,
Nakamura, R., Snyder, D.S., Chang, K., Pullarkat, V., Forman, S.J.
City of Hope Comprehensive.
Between 1/1/2000 and 12/31/2004, 22 patients (pts) with either
AML with antecedent MDS (18 pts) or therapy related AML (4
pts) received (RIC) for allogeneic HCT from either HLA matched
sibling or unrelated donor (MRD) (11 pts each). The median age
was 60.5 yrs (range 30-71). The majority of patients were in
remission (CR  12, CR2  2) but 8 pts had active disease (3
induction failure, 3 relapse and 2 untreated); marrow blasts in this
group ranged from 8% to 80% with 10% circulating blasts at
HCT in all but one. Cytogenetic risk groups were unfavorable (8),
intermediate (13) and favorable (1). Fludarabine (FLU) and mel-
phalan (Mel) was the (RIC) 19 pts; FLU and TBI 200 cGy in 2 pts
and FLU/BU, in 1 pt GVHD prophylaxis was CSP MMF in 10
pts, CSA MMF MTX in 11 pts, and FK 506 MTX in 1 pt.
Stem cell source was PBSC in 21. Median time to WBC 	500 was
15 days (6-27) and plts 	20000 was 18 days (1-32 d). Grade 2-4
acute GVHD occurred in 12 pts (54%) while 15 pts (67%) at risk
developed chronic GVHD. The day 100 mortality was 23%. With
a median follow up of 24 months, 11 pts are alive with 10 in
remission for an OS of 49% and a DFS of 45%. Six pts relapsed (5
sibling and 1 URD) (relapse rate, 36%). There was no signiﬁcant
difference between OS and EFS based on age, cytogenetics, remis-
sion status or donor source although there was a trend (P .06) for
relapse base on donor source. Reduced intensity conditioning of-
fers improved survival for patients with high risk AML when
compared to conventional chemotherapy. Treatment related mor-
tality is acceptable but further efforts are needed to reduce relapse
in related donors.
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REDUCED INTENSITY MATCHED RELATED (MRD) AND MATCHED UN-
RELATED (MUD) ALLOGENEIC STEM CELL TRANSPLANTATION (RIST)
IN ADULTS WITH MYELODYSPLASTIC SYNDROME (MDS) AND ACUTE
MYELOID LEUKEMIA (AML): A SINGLE CENTER EXPERIENCE
Kassim, A.A.1, Jagasia, M.H.1, Vusirikala, M.2, Dixon, S.L.1,
Chinratanalab, W.2, Morgan, D.S.1, Ruffner, K.L.1, Greer, J.P.1,
Stein, R.S.1, Goodman, S.A.2, Mineishi, S.1, Schuening, F.G.1 1.
Vanderbilt University Medical Center, Nashville, TN; 2. Veterans Ad-
ministration Medical Center, Nashville, TN.
Introduction:The median age of diagnosis in AML is more than
60 years, and adequate management of AML in older patient’s
remains controversial. Due to an increase in comorbid illnesses,
graft versus host disease (GVHD) with aging and arbitrary age
limit for allogeneic stem cell transplantation is 55 years in many
centers. RIST can potentially reduce treatment related mortality of
older patients and provides the curative potential of allogeneic cell
therapy. Methods: We analyzed the outcome of 23 consecutive
patients with AML or MDS, undergoing RIST from a MRD or
MUD. Conditioning regimen for both was ﬂudarabine (180 mg/
m2) and busulfan (PO 8 mg/kg or IV 6.4 mg/kg), plus total body
irradiation (4 Gy) for MUD. GVHD prophylaxis consisted of
cyclosporine and mycophenolate mofetil. Results: 12 patients un-
derwent a MRD and 11 had a MUD RIST. Median age at trans-
plant was 56 (range 42-67). 52% of the patients were male. Ten
patients had MDS; 12 AML and 1 myeloﬁbrosis. 16 received
peripheral blood stem cells while 7 received bone marrow trans-
plants. Median time from diagnosis to transplant was 402 days. All
patients had normal engraftment (median 17 days, platelets; 16
days, neutrophils). Survival at 100 days was 91% 1 year overall
survival is 48%, with a median follow-up of 435 days (range 53-816
days). There was no difference in survival between MRD and
MUD transplants. Three patients died of progressive disease, 1 due
to secondary malignancy and 8 from transplant related mortality.
The cumulative incidence of acute GVHD was 0 in 17%; grade I
13%; grade II 48%; III 13% and IV 9% while 2/23 had limited;
9/23 extensive chronic GVHD. Conclusion: These data suggest
that RIST is a feasible treatment option in older patients with
poor-prognosis MDS and AML. Our survival data are comparable
to similar non-myeloablative transplant approaches for these dis-
ease/age groups of patients.
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ANTIGEN SPECIFIC T-CELL RESPONSE TO ASPERGILLUS FUMIGATUS IN UN-
RELATED ALLOGENEIC TRANSPLANT RECIPIENTS
Rosenthal, H.S., Somani, J., Nolte, F.S., Waller, E.K. Emory Univer-
sity, Atlanta, GA.
Introduction: Invasive aspergillosis infection is a signiﬁcant cause
of morbidity and mortality in patients who undergo unrelated donor
allogeneic transplantation. The post transplantation period of pre-
engraftment immunosuppression is most commonly associated with
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greater susceptibility to invasive aspergillosis. T-cell secreted cytokine
response to aspergillus antigen in culture may be used to predict
patients’ ability to generate an immune response or can be associated
with disease progression. The production of -IFN is associated with
Th1 cell mediated immunity and results in greater resistance to
antigens. Production of Th2 cytokines, IL-10 and IL-4, indicates
immunosuppression and tolerance. T-cell secreted cytokines can be
detected using conventional enzyme-linked immunoassay (ELISA)
technology. The cytokine proﬁle produced during culture with as-
pergillus antigen may provide useful information on a patients ability
to mount an immune response to this speciﬁc antigen. Method: A.
fumigatus conidia were inoculated into Sabourad broth and incubated
for 42hours under appropriate conditions. The mycelial mat formed
was washed, disrupted with a homogenizer and cellular extract col-
lected. Protein content was determined using BSA standard. Antigen
was cultured initially with Ficolled mononuclear cells (MNCs) from
healthy normal donors to determine the minimum dose resulting in
best cytokine response. MNCs from patients at 3 and 6 month time
points after unrelated allogeneic transplantation were cultured withA.
fumigatus antigen at a concentration of 1  106 cells/ml. Cultures
were incubated at 37°C with 5% CO2 for 16-24 hours, centrifuged,
supernatant removed and frozen at 70°C until testing. IL-2, IL-4,
IL-10 and -IFN 96 well plate ELISA assays were performed on
thawed supernatants. Results: In patients who had undergone allo-
geneic transplants, 22 of 30 (73%) had higher IL-10/-IFN ratios
(34.0; range 0.03-486.7) at 3 months post transplant. In contrast, at 6
months, 8 of 14 (57%) had a higher IL-10/-IFN ratio (27.1; range
0.03-217.8). IL-2 secretion was undetectable in all 3 and 6 month post
transplant samples. Conclusions: Higher IL-10/-IFN ratios in pa-
tients at 3 months post-allogeneic transplant suggests a Th2 or more
immunosuppressive response to aspergillus. At 6 months post-trans-
plant, the average IL-10/-IFN ratio decreases which suggests an
increase in the number of patients able to demonstrate a Th1 cell
mediated immune response to A. fumigatus.
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DISEASE STATUS AT TRANSPLANT IMPACTS LYMPHOCYTE AND PLATE-
LET RECOVERY AFTER ALLOGENEIC PERIPHERAL BLOOD STEM CELL
TRANSPLANT (PBSCT) FOR PATIENTS WITH AML/MDS
Saliba, R.M.1, Oran, B.1, Giralt, S.1, Komanduri, K.1,
Carrasco-Yalan, A.2, Ghosh, S.1, Champlin, R.1, de Lima, M.1 1.
Department of Blood and Marrow Transplantation, U.T. M.D. Ander-
son Cancer Center, Houston, TX; 2. CECLA, Mexico.
Lymphocyte and platelet count have been correlated with outcomes
of allogeneic SCT. We sought to test this hypothesis in a homoge-
neous group of patients with AML/MDS. Patients andMethods: 54
consecutive patients with high-risk AML/MDS received a matched-
sibling PBSCT with ﬂudarabine (100-180 mg/m2) and melphalan
(100-180mg/m2) conditioning and tacrolimus-basedGVHDprophy-
laxis between 1996 and 2003. Median age was 55 years (23-68).
Disease status at PBSCT was complete remission (CR, 15/54), No
CR with (NoCR/CB, 15/54) or without circulating blasts (NoCR/
NoCB, 24/54). Cytogenetics were high-risk in 45% of patients, in-
termediate in 46%, unknown in 9%. Cox’s regression analysis was
used to evaluate predictors of outcome at landmarks starting at day 30
post-SCT. We evaluated day 30 lymphocyte and platelet count (cat-
egorized at the respectivemedians: 760 109/L and 80 109/L), age,
cytogenetics, disease status at transplant, ﬁrst remission duration, and
grade II-IV acute GVHD (a-GVHD) and chronic GVHD as time-
dependent variables.Results: 51/54 patients were alive by day 30, and
47/51 (92%) had achieved a CR; 40/44 patients tested achieved 100%
donor chimerism. Actuarial survival for these 47 patients in CR was
51% and disease progression 36% at 3 years. Grade II-IV a-GVHD
was the only signiﬁcant predictor of mortality at 3 years (HR  2.8,
P .02). Disease status of NoCR/CB at PBSCT (HR 2.3, 95% CI
0.9-6), lymphocyte (HR  1.8, 95% CI 0.8-4) and platelet count
below the median (HR  1.6, 95% CI 0.7-4) showed a trend for
higher mortality. Disease status of NoCR/CB at PBSCTwas the only
signiﬁcant predictor of disease progression (HR  4.6, P  .003).
Lymphocyte count below the median showed a trend for higher
progression rate (HR  2.8, 95% CI (0.96-8)), in contrast to low
platelet count (HR 1.1 (95%CI 0.4-3)). A stratiﬁed analysis showed
that patients who were in CR at PBSCT achieved the highest count
on average, followed by the NoCR/NoCB and the NoCR/CB groups
(Table 1). A similar pattern was observed excluding patients diagnosed
with a-GVHD by day 30, or stratifying by the dose of melphalan in
the preparative regimen. Conclusion: Among patients in CR after
PBSCT for AML/MDS, day 30 lymphocyte and platelet counts are
highly correlated with disease status at PBSCT. This illustrates the
limited usefulness of these variables as independent predictors of
outcome and highlights theassociation of disease status at PBSCT and
delayed early lymphoid reconstitution (Table 1).
Table 1. Lymphocyte and Platelet Count (109/L) on Day 30 post
Transplant for Patients Who Were in CR at That Time According to
Disease Status at the Time of Transplant
CR
(n  15)
*No CR/No
CB
(n  19)
*No
CR/CB
(n  13)
Test for
Trend
(P Value)
Median
lymphocyte
count (range)
1010 (230–1770) 760 (220–3500) 470 (70–1820) .10
Median platelet
count (range)
114 (16–64) 75 (21–189) 61 (11–279) .03
Days to platelet
count 20K
(range)
14 (10–24) 15 (7–72) 22 (10–72) .01
Excluding patients
with a-GVHD
by day 30
n  11 n  15 n  8
Median
lymphocyte
count (range)
1030 (380–1770) 770 (260–3500) 560 (70–119) .03
Median platelet
count (range)
114 (56–164) 85 (21–189) 53 (31–121) .04
*CR: complete remission, CB: circulating blast.
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NON-MYELOABLATIVE HEMATOPOIETIC STEM CELL TRANSPLANTA-
TION (NMT) IS WELL TOLERATED AND EFFECTIVE IN ASIAN PATIENTS
WITH HIGH RISK HEMATOLOGICAL MALIGNANCIES
Chen, C.-S.1,2, Yusof, N.2, Tan, B.2, Law, P.1,2, Soh, T.G.2, Yasir, F.2,
Tan, L.K.2 1. National University of Singapore, Singapore, Singapore;
2. National University Hospital, Singapore, Singapore.
Aims:To evaluate the safety and feasibility of NMT for high risk
diseases in Asian patients excluded from conventional allogeneic
transplant due to co-morbidity, we initiated an IRB-approved pro-
tocol adapting published conditioning regimen with ﬂudarabine
(day 4 to 2, total 90 mg/m2) and TBI (day 0, 200 cGy).
However, GVHD prophylaxis was modiﬁed with the combination
of cyclosporin, mycophenolate mofetil and methotrexate (day 1, 3,
6, and 11). IVIG was given bi-weekly until day 100. Methods: 13
eligible patients with matched sibling donors (10/3 M/F) enrolled
with median age 42 (range: 19-62). Peripheral blood stem cells
were collected after G-CSF mobilization. Diseases included my-
elodysplastic syndrome (MDS-RA and RAEBT) (n  5), multiple
myeloma (MM) (4), acute myeloid leukemia (AML) (3) and chronic
myeloid leukemia (CML) (1). Among 5 MDS, one MDS-RA pa-
tient had end stage renal failure (IgA nephropathy) on daily peri-
toneal dialysis and one had aplastic marrow not recovering after
initial induction chemotherapy. All MM patients had failed previ-
ous autologous transplants with one failed both autologous and
allogeneic transplants. Among AML patients, one had compro-
mised cardiac function unable to complete induction chemother-
apy; one had chronic hepatitis, and one with transformed AML
who did not have consolidation chemotherapy prior to transplant.
Results: A median dose of 4.71  106 CD34 cells/kg (3.05-8.15)
and 3.69  108 CD3 T cells/kg (1.85-8.12) was infused after
conditioning. Absolute neutrophil counts fell below 500/l for all
except one patient and the median duration of neutropenia was 14
days (0-20). Only 4 patients experienced thrombocytopenia (plate-
let 20000/l) and required transfusions of 2 units (median, range
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